Adverse events · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of drinking (no. days drinking/week) at 12 months · s
1 finding from 1 review
Binge drinking · s
1 finding from 1 review
Drinking Intensity · s
1 finding from 1 review
Adverse events · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quantity of drinking (g/week) at 12 months · s
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · s
1 finding from 1 review
Binge drinking · s
1 finding from 1 review
Drinking Intensity · s
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retention [ · patients with opioid dependence
Supervised dosing with a long‐acting medication showed no clear difference in retention ‐ retention at the end of treatment (number of participants) compared with unsupervised consumption (low certainty).
2 findings from 1 review
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
Abstinence from unsanctioned opioid use (number of participants with urine drug screen or self‐report use) · patients with opioid dependence
1 finding from 1 review
Diversion (number of participants) · patients with opioid dependence
1 finding from 1 review
Days of unsanctioned opioid use · patients with opioid dependence
1 finding from 1 review
Mortality ‐ (number of participants) · patients with opioid dependence
1 finding from 1 review
HCV incidence adjusted analyses number of HCV seroconversion · people who inject drugs
Current OST may leads to lower HCV incidence adjusted analyses number of HCV seroconversion compared with no OST (low certainty).
1 finding from 1 review
HCV incidence adjusted analyses number of HCV seroconversion · people who inject drugs
It is very uncertain whether high NSP coverage changes HCV incidence adjusted analyses number of HCV seroconversion compared with no/low NSP coverage (very low certainty).
1 finding from 1 review
HCV incidence adjusted analyses number of HCV seroconversion · people who inject drugs
Combined OST and high NSP may leads to lower HCV incidence adjusted analyses number of HCV seroconversions compared with no OST and low/no NSP (low certainty).
1 finding from 1 review
Participants with severe withdrawal · People undergoing managed opioid withdrawal
Alpha2‐adrenergic agonist showed no clear difference in participants with severe withdrawal compared with methadone (low certainty).
1 finding from 1 review
1Small number of events. · People undergoing managed opioid withdrawal
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported